Dr. Richard Lewanczuk is a Professor in the Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine & Dentistry, and Senior Medical Director for the Department of Primary Health Care with Alberta Health Services.
He established the first bioequivalence and pharmacokinetic-pharmacodynamic clinic trials facility in Western Canada, and was instrumental in developing the business case and plans for the current phase I clinical trials facility at the University of Alberta Hospital. He also contributed to the establishment of the Northern Alberta Clinical Trials and Research Centre (NACTRC), a joint initiative of the University of Alberta and Alberta Health Services through which all clinical trials at the University of Alberta flow.
Dr. Lewanczuk holds over 70 patents, 3 of which are currently commercialized, and has carried out over 50 clinical trials ranging from phase I to phase IV as well as pharmacokinetic-pharmacodynamic and bioequivalence trials. Many of these trials have involved natural products and traditional medicines including Chinese traditional medicine, Native North American traditional medicine, and natural products from Europe and South America. He also served as an advisor in clinical trials to the University of Hong Kong Traditional Chinese Medicine Program.
His research interests include hypertension, type 2 diabetes, cardiometabolic syndrome, obesity, and the effects of inflammation on drug pharmacokinetics-pharmacodynamics.